Close Menu

Breaking News

Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said

Researchers re-analyzed throat swabs collected from patients in Wuhan with influenza-like-illness and found that some were positive for SARS-Cov-2.

The researchers applied their approach to study the heterogeneity of immune cells and adapted a visualization tool to analyze the data.

The company said that three of its clinical laboratories have passed a COVID-19 external quality assessment by China's National Center for Clinical Laboratories.

United said it will distribute the test to international governments and healthcare organizations.

The company said its product and services revenues were about $24.5 million for the quarter, 15 percent higher than the same period last year.

Under the agreement, Bioneer will supply instruments, nucleic acid extraction reagents, and COVID-19 test kits, which will be placed at medical institutions in Qatar.

The assay is a real-time RT-PCR test designed for the qualitative detection of specific sequences of the SARS-CoV-2 N gene in respiratory specimens.

The multiplexed PCR-based test will use Aegea's technology to measure the virus from nasal or other swabs, even in asymptomatic patients.

The company said that its preliminary revenues are expected to be down almost 8 percent year over year due to the pandemic.

The PCR-based test is designed to detect the nucleocapsid gene of the SARS-CoV-2 virus in nasal, nasopharyngeal, and oropharyngeal swab specimens.

Luminex said that its Q1 molecular diagnostics revenues are anticipated to rise more than 25 percent year over year, driven by SARS-CoV-2 test sales.

Both the Israeli and Palestinian authorities have granted approval for the lab to perform 3,000 COVID-19 tests per day for Gaza residents.

The NIGMS repository holds and distributes over 11,700 unique cell lines, as well as more than 6,300 DNA samples, representing over 1,000 heritable diseases.

The three hospital laboratories' tests are all real-time PCR assays for detecting the virus from nasopharyngeal swabs and bronchoalveolar lavage.

Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.

Last week, GenomeWeb's readers were most interested in new EUA guidance from the FDA for molecular-based laboratory developed tests detecting SARS-CoV-2.

The company said that as the COVID-19 pandemic spread throughout the world, it saw a "significant reduction in customer activity" by late March.

Luminex said that with two FDA EUAs it is now providing SARS-CoV-2 diagnostic tests for high-complexity, high-throughput labs and moderate-complexity testing facilities.

The test is a real-time RT-PCR kit designed to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs, as well as bronchoalveolar lavage.

The PCR-based test, which recently received CE-IVD marking, uses Co-Diagnostics' CoPrimer technology to detect the RdRp gene of the SARS-CoV-2 virus.

The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.

MicroGen Dx's Texas-based lab is the only commercial laboratory in the US offering sputum testing for SARS-CoV-2.

The approach deconvolutes admixed individuals' ancestries and develops polygenic risk scores based on each component that can then be combined.

After validating its pathogen detection platform for multiple viruses, the firm aims to initially offer a point-of-care diagnostic testing panel by the third quarter.

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.